Moving PARP Inhibition Upfront: Why the Phase 3 TALAPRO-3 Trial Rewrites Treatment for HRR-Deficient mCSPC
ASCO 2026 data suggest first-line talazoparib plus enzalutamide significantly delays progression in HRR-mutated metastatic prostate cancer, highlighting the growing importance of early genomic testing and biomarker-driven treatment.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.